MPR Weekly Dose

This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola. 

This week on the pod; the latest COVID news, including encouraging news on antibody therapies; Updated on Emergency Use Authorization guidelines for vaccines; Remdesivir distribution; A HIV drug fails to have an impact; And why the FDA want a preterm birth treatment withdrawn from the market.

New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval. Also we look at this week's developments in drugs in the pipeline.

This week we cover AstraZeneca and the swift decision to restart their COVID-19 vaccine candidate trial; Pfizer and BioNTech want to expand enrollment for their   candidate vaccine trial; There's the janus kinase inhibitor that could help reduce recovery time; An investigative antiviral may ease strain on hospitalizations; Aortic aneurysm, dissection assessed with fluoroquinolones; and a retrospec...

We cover AstraZeneca's decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we  wrap up the latest news on drugs in the pipeline.

The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there's developments in convalescent plasma authorization; A 15 minute test; And ethnobotanist's give a stark warning concerning a plant that some are touting as a cure; In other news an intrauterine device gains expanded approval; Label update for hydrochlorothiazide.

Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it's shelf life extended. Also, we recap drug pipeline news from the past week.

Remdesivir is submitted; New opioid approved by FDA; A new Spinal Muscular Atrophy treatment;  A sublingual epinephrine treatment; and the latest on Biogen's investigational Alzheimer disease treatment.

This week there's more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaski...

It's been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There's results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting sars-cov-2; And  researchers have linked vaccination to reduced risks of Alzheimer disease.

This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there's new treatment for narcolepsy.

This week; Significant moves in COVID-19 vaccine development; Research finds a link between PPI use and increased risk of COVID-19; We look at remdesivir's efficacy in severe COVID-19 cases; And several Company's recall their metformin extended release tablets.

The discontinuation of a trial investigating a potential COVID-19 treatment; A safety alert for toxic hand sanitizers; Vaccine guidance in the time of the pandemic; And new treatments in HIV and myelodysplastic syndromes.

This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there's a new drug approvals in breast cancer and Dravet syndome.

This week on the Pod: Over-the-counter med recalls; a nasal spray approved for diabetic gastroparesis; reports of an uptick in p enicillin-, ciprofloxacin-resistant meningococci; and in pandemic-related news, a possible inhaled version of remdesivir, and colchicine as a potential treatment. 

This week we cover the latest in the rapidly shifting perception of chloroquine and hydroxychloroquine; The polio vaccine as a potential protector against COVID-19; A new approval for Gardasil 9; And the American Gastroenterological Association draw up new guidelines for probiotic use as a treatment in gastrointestinal disorders.

This week on the pod we cover the latest COVID19 news, including  antibody tests and their accuracy; A study aiming to examine treatments in children; The potential benefit of Acalabrutinib in severe cases; The WHO's Technical Lead on COVID-19 having to backpedal a statement on transmission; And many states lodge record high numbers of infections.

This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins. 

Today's pod covers important news regarding hydroxychloroquine; The efficacy of dietary supplements as a means to manage or prevent COVID-19; The first non-hormonal contraceptive gel approved by the FDA; And an expanded approval for dupilumab.

This week we cover the latest COVID-19 developments including: reports of false negatives with Abbott's diagnostic test; the immune globulin therapy linked to recovery in multisystem inflammatory syndrome in children, related to COVID-19; and the clinical trials set to be initiated for an umbilical cord stem cell therapy and a high dose IV immune globulin therapy.

This week we cover the latest COVID-19 developments including a triple antiviral therapy that looks promising, Emergency Use Authorizations granted to diagnostics and critical meds, Moderna's investigational vaccine gets Fast Tracked, and the National Institute of Health's remdesivir plus baricitinib trial.

This week we cover the the risk of antihypertensive med use during the pandemic; The Emergency Use Authorization for remdesivir in hospitalized patients with suspected or confirmed COVID-19; The addition of a Boxed Warning to Montelukast; A new Farxiga indication; And a novel treatment for acute migraines.

There has been a lot of recent developments in possible COVID-19 treatments. I'll go over the latest status with remdesivir, hydroxychloroquine, sarilumab, and remestemcel-L, and also the treatment guidelines for COVID-19 issued by the National Institute of Health. 

On today's podcast we run through the top COVID-19 stories including a steep rise in poison control calls; the authorization of an at-home testing kit; The hydroxychloroquine trial that's beginning soon; The trial evaluating ruxolitinib for COVID-19 associated cytokine storms; and the lab failures which have led to ineffective COVID-19 tests being sent from the CDC to nearly all of the 100 state a...

We run through the latest COVID-19 news including results from a remdesivir trial; The blood purification system OK'd for patients in the ICU; A chloroquine trial halted early due to deaths; The saliva test that detects COVID19; And a bleaching agent product that is claiming to prevent COVID-19.